by Dixie Lawrence | Sep 28, 2026 | Research
Rationale for the Use of Kaempferia parviflora (Black Ginger) as a Neuroprotective Anti-Inflammatory Agent Targeting Microglial Hyperactivity 1. Introduction and Clinical Need Chronic neuroinflammation driven by microglial hyperactivity is a primary pathophysiological...
by Dixie Lawrence | Sep 27, 2026 | Research
The most DS-specific target: RCAN1 RCAN1 (also called DSCR1) sits in the Down syndrome critical region on chromosome 21. Extra copy number raises RCAN1 protein, which: • increases mitochondrial and cellular ROS, • activates NF-κB, • induces the apoptosis adaptor...
by Dixie Lawrence | Sep 27, 2026 | Research
Pathways and genes most likely to be affected 1. APP processing and amyloid pathology People with DS carry three copies of APP and develop Alzheimer-type plaques decades earlier than the general population. In APP/PS1 and 5xFAD mice, hesperidin. • reduces Aβ...
by Dixie Lawrence | Sep 27, 2026 | Research
Luteolin (often misspelled Leuteolin) and rutin do not directly silence or reduce the extra copy of chromosome 21 genes. They act downstream on the consequences of that overexpression—especially neuroinflammation, oxidative stress, APP/Aβ-related pathology, and...
by Dixie Lawrence | Sep 27, 2026 | Research
Apigenin is a multi-target dietary flavonoid with preclinical support as a candidate therapy for Down syndrome (DS/trisomy 21), acting on CBS overexpression plus several other Hsa21-linked and secondary pathways that drive oxidative stress, neuroinflammation, impaired...
by Dixie Lawrence | Sep 27, 2026 | Research
1. Why formulation is the first scientific point Unformulated curcumin has oral bioavailability well under 1%. It is rapidly glucuronidated and sulfated in intestine and liver; free parent curcumin in plasma is often undetectable. Most in-vitro targets (NF-κB, Aβ...
English
Español de México
Português
Français